

Emergency Medicine Reports

The Practical Journal for Emergency Physicians

Volume 33, Number 9 / April 9, 2012

www.emreports.com

Author:

Ademola Adewale, MD,
FAAEM, Assistant Professor of
Emergency Medicine, Florida
State University College of
Medicine, Director of Research
and Medical Simulation, Florida
Hospital Emergency Medicine
Residency Program, Orlando, FL.

Peer Reviewer:

Bentley J. Bobrow, MD,
Associate Professor of Emergency
Medicine, Emergency Medicine
Department, Maricopa Medical
Center, Phoenix, AZ.

Statement of Financial Disclosure

To reveal any potential bias in this publication, and in accordance with Accreditation Council for Continuing Medical Education guidelines, we disclose that Dr. Farel (CME question reviewer) owns stock in Johnson & Johnson. Dr. Stapczynski (editor) owns stock in Bristol Myers Squibb. Dr. Schneider (editor), Dr. Adewale (author), Dr. Bobrow (peer reviewer), Ms. Mark (executive editor), and Ms. Hamlin (managing editor) report no financial relationships with companies related to the field of study covered by this CME activity.

The Evidence-based Approach to Neurologic Emergencies: Part I: Acute Stroke

Stroke remains a leading cause of death, but the disability associated with a stroke can be devastating and costly. In past decades, little could be done to reduce the morbidity and mortality of stroke. But over the past decade, use of thrombolytics by specialized stroke centers has reduced the morbidity of survivors. However, the reduction of morbidity comes at a cost of an increase in intracerebral hemorrhage, often associated with death.

Some emergency physicians have been reluctant to use thrombolytics in their patients with stroke. In large part that is due to the risk of intracranial hemorrhage, but it is also often due to the lack of a neurology specialist 24/7 to assist with the interpretation of the CT scan and back-up by neurosurgical specialists in case something untoward should occur. Many are concerned about the medical liability risk that may occur if they either order or fail to order thrombolytics.

Despite these concerns, there are now clear guidelines for the use of thrombolytics in stroke patients. This paper will review the most recent guidelines to assist physicians who work in centers with sufficient support to offer thrombolytic therapy for stroke.

— Sandra M. Schneider, MD, FACEP, Editor

Introduction

Neurologic emergencies are common presentations to the emergency department (ED). Emergency physicians should have a broad-based understanding of the disease process and the best evidence-based approach to care for these patients to minimize morbidity and potential mortality. A neurologic emergency encompasses a broad variety of disease pathology; thus, it is impossible to discuss the entirety in a single paper. This paper will focus on one of the most common life-threatening entities: acute stroke.

- Stroke in the United States is the leading cause of death; more than 800,000 people die each year from stroke and cardiovascular disease.¹
- Someone has a stroke every 40 seconds. Someone dies of stroke every 4 minutes.²
- On a yearly basis, about 795,000 people have a stroke.
- More than 600,000 of these are first time or new strokes.
- Almost 185,000 people who survive a stroke have a second stroke.²
- Stroke is an important cause of disability, and in 2005 almost 1.1 million survivors reported having difficulty performing daily tasks.³
- The cost of stroke care is staggering. In 2010 alone, the estimated cost of stroke care was \$53.9 billion.²

Incidence

The incidence of stroke varies widely depending on age, sex, ethnicity, and socioeconomic status. The American Heart Association (AHA) data⁴ suggest

Executive Summary

- Stroke and cardiovascular disease are the major causes of mortality in the United States.
- Occlusion of the middle cerebral artery is the most common cause of stroke and typically presents with hemiparesis with or without speech problems. However other stroke syndromes can occur.
- Thrombolysis, when used in appropriate patients and appropriate settings, can reverse stroke symptoms in some patients. However, it carries the small but important risk of intracerebral hemorrhage.
- Control blood pressure to < 185/110 mm Hg before administration of thrombolytics. Reduce blood glucose to less than 150 mg/dL.

that blacks have a 3-fold higher multivariate-adjusted risk of lacunar stroke compared to whites. While typically stroke occurs in older adults, stroke can be seen in younger adults and even children, especially those with chronic disease such as sickle cell and those with cardiac defects such as patent ductus arteriosus. According to the Centers for Disease Control (CDC), about 85% of strokes are ischemic, while 10-12% are hemorrhagic. Transient ischemic attacks (TIA) and cryptogenic stroke are the remaining 3-5%.⁴

Risk Factors

The risk factors (*see Table 1*) for stroke are similar for all stroke types: hypertension, advanced age, previous history of a stroke, and illicit drug use. However, in hemorrhagic stroke, certain factors such as anticoagulation therapy, arteriovenous malformation, cerebral amyloidosis, coagulopathies, intracranial aneurysm, neoplasm, vasculitis, and thrombolytic therapy are significant contributors.

The Common Blood Vessels in Stroke

Stroke presentation varies widely depending on the cerebral blood vessel involved. (*See Table 2.*) The major blood vessels of the brain are the right and left common carotids and the vertebral arteries. These two blood vessels merge to form the circle of Willis at the base of the brain. Vessels that emanate from the circle are the anterior cerebral artery (ACA), the middle cerebral artery (MCA), and the posterior cerebral artery (PCA). Emanating from the

Table 1: Risk Factors for Stroke

Modifiable	Not Modifiable
<ul style="list-style-type: none"> • High blood pressure • Cigarette smoking • Transient ischemic attacks • Heart disease • Diabetes mellitus • Hypercoagulopathy • Carotid stenosis • Atrial fibrillation 	<ul style="list-style-type: none"> • Age • Gender • Race (African American) • Prior stroke • Heredity (family history of stroke)

brainstem are the vertebral arteries that give off the anterior inferior cerebellar artery (AICA). It continues as the basilar artery (BA), which gives off the posterior inferior cerebellar artery (PICA) and superior cerebellar artery, before merging with the circle.

The anterior cerebral artery supplies the frontal lobes (responsible for the control of logical thoughts, personality, and voluntary movements), and most of the medial surface of the cerebral cortex. Unilateral infarct involving this region results in contralateral sensory and motor deficits, which preferentially involves the lower extremities. The bilateral involvement of the ACA at their stems results in infarct involving the anterior medial aspect of the cerebral cortex. This infarct results in paraplegia of the lower extremities, incontinence, and a phenomenon known as akinetic mutism that manifests as motor aphasia and abulia (lack of ability to act or make decisions) and a profound frontal lobe release symptoms (personality change).

The middle cerebral artery (MCA) is the largest of the cerebral arteries and it is by far the most common

blood vessel involved in stroke.

The cerebral cortex supplied by the MCA is vast. It supplies the majority of the outer convex of the brain, almost all the basal ganglia, and the anterior and posterior internal capsules. Simply put, it supplies the primary motor areas of the face, throat, hand, arm, and the area of speech in the dominant hemisphere. Infarct involving this vessel manifests as a myriad of neurologic sequelae, which include contralateral hemiplegia involving the face, arms, and legs, homonymous hemianopsia, and global aphasia if the infarct involves the left cerebral hemisphere.⁵

The posterior cerebral artery (PCA) often emanates from the basilar artery or terminal branch of the basilar artery in most individuals, but sometimes from the ipsilateral internal carotid arteries.⁵ This vessel supplies the posteromedial temporal lobes and occipital lobes of the cerebral hemispheres. Infarcts in this area account for approximately 5-10% of ischemic stroke and often result as a consequence of an embolism from the vertebral basilar system. PCA infarcts often manifest as thalamic or thalamic perforate syndrome

Table 2: Stroke Syndromes

Vessel	Territory	Clinical Presentation
Anterior cerebral	Frontal lobes Personality, voluntary movement	Uncommon stroke. Unilateral may be silent Contralateral leg weakness Bilateral: akinetic mutism (inability to move or speak) Confusion
Middle cerebral	Some frontal lobe Lateral surface of temporal and parietal lobes Basal ganglia Anterior/posterior internal capsules	Contralateral ataxia and hemiparesis Inability to write, calculate, right-left confusion Contralateral homonymous hemianopia, receptive aphasia, apraxia Contralateral hemiparesis, facial weakness, sensory loss, expressive aphasia
Posterior cerebral	Temporal lobe Occipital lobe	Lethargy/agitation, hemiplegia hemisensory loss, ophthalmoplegia Homonymous hemianopia Visual agnosia Inability to interpret vision, poor hand eye coordination, apraxia of gaze Inability to recognize faces Alexia (inability to read) Disorder of color vision Memory impairment Contralateral ataxia, oculomotor palsy Cortical blindness (Anton syndrome) Contralateral hemisensory loss or pain (thalamic syndrome) Contralateral hemiparesis with lateral gaze weakness (Weber syndrome) Locked in
Basilar	Cerebellum, pons, brainstem	Cortical blindness Contralateral hemiparesis, ipsilateral facial and lateral gaze weakness
Vertebral artery	Brainstem, cerebellum	Ipsilateral facial sensory loss and pain, ataxia, nystagmus, Horner's syndrome, contralateral hemisensory loss to pain and temperature (Wallenberg syndrome)
Lenticulostriate arteries	Deep branches off MCA	Lacunar infarctions

Adapted from www.strokecenter.org. Accessed April 2012.

(contralateral hemianesthesia, loss of sense of position resulting in ataxia, excruciating pain on affected side), Weber's syndrome (contralateral upper and lower extremity weakness, and ipsilateral lateral gaze weakness), hemianopsia, and a myriad of other symptoms, such as acute visual loss, dizziness, nausea, and language disorder. However, occipital lobe infarct is the most common finding and it presents as a contralateral visual field defect.⁵

Infarcts involving lenticulostriate

arteries and the penetrating branches of the circle of Willis, vertebral, and basilar arteries result in lacunar-type strokes. Lacunar type strokes account for about 20% of all strokes, and the most common risk factor is hypertension.⁶

Case Example

A 64-year-old man arrived via EMS with difficulty speaking and left side weakness. He was last seen well two hours ago. He is currently unable to speak or move his left side.

His initial vital signs reveal a blood pressure of 224/121, pulse of 98, oxygen saturation of 99%, respiratory rate of 18, GCS 12, and the EMS blood sugar of 228 mg/dL. A non-enhanced CT scan of the brain shows no hemorrhage but does show the presence of a clot within the right MCA (the hyperdense MCA sign). (See Figure 1.)

A CT angiogram of the head and neck (CTA) and CT perfusion were ordered, and the stroke neurologist was promptly consulted. The stroke

Figure 1: Hyperdense MCA Sign



A noncontrast CT scan of the patient showing thrombus within the right MCA. This is referred to as the hyper-dense MCA sign. This is one of the early signs of ischemia.

Table 3: Cincinnati Prehospital Stroke Scale

	Normal	Abnormal
Facial Droop	Both sides of face move equally	One side of face does not move
Arm Drift	Both arms move equally	One arm drifts compared to the other
Speech	Patient uses correct words with no slurring	Slurred or inappropriate words or mute

neurologist confirmed the diagnosis of acute ischemic stroke.

Ischemic Stroke

Ischemic stroke results from vessel occlusion that reduces the blood flow to the perfused area of the brain. Embolic stroke accounts for 15-30% of all strokes. In a study by Moulin et al,⁷ cardio-embolism accounted for about 50% of MCA strokes, 34% of deep MCA strokes, and 41% of cortical strokes. In embolic stroke, a dislodged plaque or embolus travels to distal arteries

or arterioles eventually disrupting the blood supply. In a thrombotic stroke, the obstruction occurs from a formed thrombus or a plaque that slowly propagates until large enough to completely occlude a vessel. The resultant manifestation is a cascade of cellular or microcellular events that lead to cerebral infarction. The pathophysiology of these cellular and microcellular cascades involves the release of excitatory amino acids, neurotransmitters, calcium influx into the cells, generation of free radicals, membrane depolarization, and

the eventual loss of membrane integrity of the blood-brain barrier.⁷

The presentation of a stroke varies with the vessel involved. For the purpose of this section, emphasis will be placed on MCA infarct since this is the most common blood vessel involved in ischemic stroke.

Management

The management of stroke patients starts pre-hospital. The initial identification of a stroke patient and rapid transport to the appropriate facility may improve outcome. Several scoring systems have been developed for the prehospital personnel to aid in rapid identification of potential stroke patients. These scores include the ABCD score, the Los Angeles Pre-hospital Stroke Scale (LAPSS), and the Cincinnati Stroke Scale. (See Table 3.)

On arrival of this patient to the emergency department, the following sequence of events should occur rapidly and simultaneously with the understanding that the goal to reperfusion is 60 minutes from arrival (see Table 4):

- Determine and confirm the last time seen normal;
- Establish IV access;
- Draw routine laboratory studies, order noncontrast CT scan;
- Perform detailed neurological examination using the screening assessment tools such as the NIH stroke scale (NIHSS);
- Monitor blood pressure;
- Obtain a 12-lead electrocardiogram (ECG) and assess for arrhythmia;
- Review CT scan to exclude hemorrhage;
- Exclude the presence of abnormal lucency on the CT scan;
- Consult stroke neurologists;
- Review laboratory test results;
- Review inclusion and exclusion criteria for initiation of thrombolytic (see Table 5).

Therapeutic Intervention

Intravenous Recombinant Tissue Plasminogen Activator (tPA). While the inclusion and exclusion criteria are reviewed, the family

asks about the possibility of “clot-busting” drugs. The patient’s family members are informed of the risks involved and believe the patient would want thrombolytic therapy.

Thrombolysis with tPA is the indicated treatment for appropriate patients with acute stroke. While there is substantial evidence that it improves outcomes, there are potential serious side effects, most importantly the risk of intracranial bleeding.

The early recommendation for tPA utilization was for patients whose last time seen normal was less than 3 hours ago. However, recent studies suggest that the time window can be extended from 3 to 4.5 hours in some patients. The observational data from the SITS-ISTR study (Safe Implementation of Thrombolysis in Stroke-International Stroke Treatment Registry)⁸ suggest there are no differences in outcomes for patients who received tPA within 3 hours compared to those who received the drug between 3-4.5 hours after the onset of stroke symptoms.

Other studies^{9,10} have supported the extension of the therapeutic window from 3 to 4.5 hours. The ECASS 3 study¹⁰ (European Cooperative Acute Stroke Study 3) was a multicenter, placebo-controlled RCT. It enrolled a total of 821 patients and utilized the current tPA regimen guidelines with the following exclusions: NIH stroke scale > 25, current use of oral anticoagulants, age greater than 80 years, and history of stroke and diabetes. The study found that disability at 90 days was significantly better in the treatment group, although the incidence of symptomatic intracranial bleed was higher. The mortality in both groups (treatment and placebo) were similar. Based on the results of the SITS-ISTR and ECASS 3 study, some advocate extending the window for tPA to 4.5 hours, although this is not FDA approved.

The recommended dosing guideline for tPA in acute ischemic stroke is 0.9 mg/kg (maximum of 90 mg) single dose, with an initial 10% of the

Table 4: NIH Treatment Guideline/Sequence Considering the “Golden Hour”

Emergency department arrival to initial physician evaluation: 10 minutes

Emergency department arrival to stroke team notification: 15 minutes

Emergency department arrival to CT scan initiation: 25 minutes

Door to CT scan interpretation: < 45 minutes

calculated dose (not to exceed 90 mg) given as a bolus over 1 minute and the rest infused over one hour.¹⁰

Thrombolysis should be considered for patients that meet the criteria in those hospitals that have systems in place for its safe administration. Despite the evidence supporting thrombolytics in both the 3 and extended 4.5 hour window, there is still some resistance to giving the drug. Clearly there needs to be institutional support available for the emergency physician, particularly in smaller, more rural hospitals. Where there is support, use of thrombolytics has become common practice.

In the case example, the initial blood pressure of the patient was 224/121. Reviewing the inclusion and exclusion criteria, this is a contraindication to initiation of intravenous thrombolytics until the blood pressure is controlled.

Blood Pressure Management in Acute Ischemic Stroke

For patients receiving tPA, control of the blood pressure is very important. Studies have shown that markedly increased blood pressure may increase the risk for intracerebral hemorrhage.¹¹ The current treatment guidelines stipulate treatment of blood pressure to achieve a systolic of 185 mm Hg or lower and a diastolic of 110 mm Hg or lower before tPA is administered.

The 2007 American Heart Association (AHA) guideline suggests intravenous labetalol 10-20 mg (bolus) as a first-line drug for rapid control of blood pressure. This could be followed by repeated boluses

(up to 300 mg) or the initiation of labetalol drip at 2-8 mg/hour until the desired blood pressure is accomplished. The 2010 AHA guidelines list intravenous nicardipine and labetalol as the first-line agents for rapid blood pressure control. When using nicardipine, start the infusion at 5 mg/hour and titrate up 2.5 mg/hour every 5-15 minutes as needed to a maximum of 15 mg/hour. When the desired blood pressure is reached, the dose can be reduced by 3 mg/hour.¹² The blood pressure should be monitored every 15 minutes during the treatment, and then for another 2 hours. For the next 6 hours, it should be monitored every 30 minutes, and every one hour for the next 16 hours.¹²

In the case example, the patient’s blood pressure was controlled with intravenous nicardipine, as per guidelines, to achieve a systolic blood pressure of less than 185 mm Hg and a diastolic BP less than 110 mm Hg. Aggressive treatment of blood pressure also comes at a cost and could be detrimental to the patient. The ischemic penumbra is defined as the area of the brain tissue that is perfused but at the threshold of functional impairment and morphologic integrity that has the capacity to recover if perfusion is promptly restored.¹³ Aggressive control of blood pressure can compromise the flow to the ischemic penumbra by creating an environment of relative hypotension or a state of hypoperfusion. This eventually leads to the death of potentially salvageable brain tissue.¹⁴

In the case example, while preparing the tPA, the remainder of the patient’s laboratory study returned

Table 5: Inclusion and Exclusion Criteria for Intravenous tPA Therapy in Patients with Acute Ischemic Stroke

<p>tPA Indications</p> <ul style="list-style-type: none"> • Ischemic stroke onset within 3 hours of drug administration. • Measurable deficit on NIH Stroke Scale examination. • Patient's computed tomography (CT) does not show hemorrhage or non stroke cause of deficit. • Patient's age is > 18 years. <p>Do NOT administer tPA if any of these statements are true:</p> <ul style="list-style-type: none"> • Patient's symptoms are minor or rapidly improving. • Patient had seizure at onset of stroke. • Patient has had another stroke or serious head trauma within the past 3 months. • Patient had major surgery within the last 14 days. • Patient has known history of intracranial hemorrhage. • Patient has sustained systolic blood pressure > 185 mmHg. • Patient has sustained diastolic blood pressure > 110 mmHg. • Aggressive treatment is necessary to lower the patient's blood pressure. • Patient has symptoms suggestive of subarachnoid hemorrhage. • Patient has had gastrointestinal or urinary tract hemorrhage within the last 21 days. • Patient has had arterial puncture at noncompressible site within the last 7 days. • Patient has received heparin with the last 48 hours and has elevated PTT. • Patient's prothrombin time (PT) is > 15 seconds. • Patient's platelet count is < 100,000 μL. • Patient's serum glucose is < 50 mg/dL or > 400 mg/dL. <p>tPA Relative Contraindications</p> <p>If either of the following statements is true, use tPA with caution:</p> <ul style="list-style-type: none"> • Patient has a large stroke with NIH Stroke Scale score > 22. • Patient's CT shows evidence of large middle cerebral artery (MCA) territory infarction (sulcal effacement or blurring of gray-white junction in greater than one-third of MCA territory). <p>Adapted from the clinical policy of the American College of Emergency Physicians.</p>
--

and revealed a blood glucose of 265 mg/dL in a nondiabetic patient. The patient was started on insulin drip as per institutional protocol, with tight monitoring of the serum glucose.

Glycemic Control. Hyperglycemia in stroke may be due to stress response with catecholamine release and it has been shown to be an independent predictor of poor outcome by inducing secondary brain injury.¹⁵

Hyperglycemia has been shown to be associated with worse prognosis in the patients receiving thrombolytic therapy.¹⁶ A study by Alvarez-Sabin et al¹⁷ evaluated the impact of admission hyperglycemia on stroke outcome after thrombolysis demonstrated that the effect of admission hyperglycemia on stroke outcome varied depending on the time to tPA reperfusion. The authors stated


that the detrimental effect of acute hyperglycemia is higher after early reperfusion than after delayed or no reperfusion, and suggested that ultra early glycemic control before reperfusion may improve the efficacy of thrombolytic therapy.

While it is appropriate to control hyperglycemia in stroke patients, the ideal glucose level is unknown. The Glycemia in Acute Stroke (GLIAS) study¹⁸ evaluated the prognostic value of capillary glucose level in acute stroke. The study demonstrated that hyperglycemia \geq 155 mg/dL at any time within the first 48 hours of stroke onset, and not only the isolated value of admission glycemia is associated with poor outcome independently of stroke severity, infarct volume, diabetes, or age. A post-hoc analysis of the GLIAS study¹⁹ evaluated persistent hyperglycemia \geq 155 mg/dL in acute stroke patients. The study demonstrated that almost 40% of patients maintained levels > 155 mg/dL despite corrective treatment, and it was associated with poorer outcome and increased mortality. According to ASA guidelines, a reasonable approach would be to initiate treatment among acute stroke patients with blood glucose > 200 mg/dL.

The available body of evidence confirms the deleterious effect of hyperglycemia in acute stroke patients and also demonstrates the threshold that correlates well with an increased mortality (greater than or equal to 155 mg/dL). The goal is to attain a target blood glucose of at least < 155 mg/dL using insulin therapy with caution to avoid overshooting and inducing a state of hypoglycemia. Baker et al²⁰ recommended that patients receiving thrombolytic therapy should be started on an established and standardized intravenous insulin protocol to improve glucose control for at least the first 24 to 48 hours of hospitalization.

In the case example, the patient received intravenous tPA with adequate monitoring of the blood pressure while the infusion was ongoing in the ED. Mid-way through the

Figure 2: CT Angiogram of a Patient Showing Flow Pattern of the Right MCA Branch



infusion, the patient indicated he was having a headache. At this time, the infusion was stopped and an emergent CT scan of the head was obtained. The scan revealed no hemorrhage, and the infusion was resumed. The patient was subsequently admitted to the neuro-critical stroke care unit.

The management of acute ischemic stroke hinges on early identification of the stroke patient, utilizing a validated screening tool, understanding the time-line for evaluation and reperfusion, and adequately screening using screening scales and the inclusion and exclusion criteria for thrombolytic intervention. In addition, following the guideline for the blood pressure control and post-tPA care relating to BP while in the emergency department is very important. Stroke-capable centers offer the benefit of a multidisciplinary approach to stroke care. If the patient presents to an ED without thrombolytic capability, consideration should be given to rapid transfer to a stroke capable center.

Situations might arise when, despite the best efforts, the last time “seen normal” cannot be delineated. In this event, a non-contrast CT scan, CT angiogram of the head and neck, and CT perfusion may be utilized to aid in the identification of patients who are candidates for acute intervention. (See Figures 2 and 3.) The CT scan perfusion enables the identification of ischemic penumbra

that may be a criterion for intra-arterial thrombolytic in academic centers that have the availability of interventional neuroradiologist or neurosurgeons on staff. In the case that these resources are not available, transfer of appropriate patients should be considered.

Radiographic Evaluation of Stroke Patients

Imaging of a stroke patient should occur promptly to avoid delays in door-to-reperfusion. The clinician should understand the implications of knowing the last time the patient was seen normal and the type of imaging needed to avoid potential delays in therapeutic intervention.

The AHA scientific statements²¹ recommend that the imaging study decided upon should definitely address the following: the presence or absence of hemorrhage; the presence of intravascular thrombus that can be treated with thrombolytic or thrombectomy; the presence and size of a core that is irreversibly infarcted; and the presence of hypoperfused tissue at risk for infarction if reperfusion is not promptly restored.

The initial radiographic study to evaluate an acute stroke patient is a nonenhanced CT scan (NECT) of the brain. Although the average sensitivity of CT in detecting early ischemia is 66%,²² it is the preferred study for initial triaging for patients being considered for thrombolytic therapy. The NECT helps detect


the presence or absence of hemorrhage or cerebral mass, or alternative diagnosis of the patients’ symptoms. NECT creates a good contrast between blood and cerebrospinal fluid. In addition, it is widely available with minimal contraindications to its utility.

When interpreting the NECT, the emergency physician should be conversant with some terminologies representing the early signs of stroke on the CT scan. These include the insular ribbon sign (loss of gray and white matter interface in the proximal region of the MCA distribution), obscuration of lentiform nucleus (loss of the outline of the lentiform nucleus of the basal ganglia), and the hyperdense MCA sign (presence of acute thrombus in the MCA). (See Figure 1.) In addition to the early ischemic signs, the clinician should understand the signs of contraindication to thrombolytics in the absence of hemorrhage.

One of these signs is obvious hypo-attenuation on the NECT. This is indicative of irreversible infarct and carries a significant risk for hemorrhagic transformation. (See Figure 4.) According to the ECASS I and II study, the involvement of more than one third of the MCA territory on NECT is an exclusion from thrombolytic therapy due to the risk of hemorrhagic transformation.^{23,24}

CT angiography (CTA) (from aorta to top of head) can easily be performed immediately after NECT,

Figure 3: CT Perfusion of the Patient with Right MCA Stroke Demonstrating the Blood Volume, Mean Transit Time, and Blood Flow



thus reducing delays. (See Figure 2.) The 3-D reconstruction of the images and blood vessels allows for the visualization of areas of stenosis, aneurysms, bleed, and other vascular abnormalities such as AVM. When imaging is obtained from the aorta to the top of the head, it will help detect the presence or absence of aortic or carotid dissection as the source of presenting symptoms. At

the same time, the source images obtained from the CTA can help identify qualitative information regarding the cerebral blood volume (CBV) map that establishes the core of infarction and the tissue at risk for infarction.

CT perfusion (CTP) is used to examine the blood flow and identify potentially salvageable hypoperfused region or the ischemic penumbra,

and areas that are completely infarcted. (See Figure 3.) Parameters such as cerebral blood flow (CBF) relates to the volume of blood flowing per brain mass in a minute), cerebral blood volume (CBV relates to volume per unit of brain), the mean transit time (MTT), and the time to peak flow (time difference between arterial inflow and venous outflow) can all be obtained. CTP is

usually performed immediately after the CTA to avoid double contrast injection.

Several factors often affect the type of imaging obtained. These may include cost of the study, institutional capability (if not a designated comprehensive stroke center), last time seen normal, the patient hemodynamic stability, and the impact on door to reperfusion. These studies could be performed simultaneously in less than 20 minutes. Viewing the NECT simultaneously as it is performed allows one to proceed immediately with the CTA and CTP.

Occasionally, the CTA will identify carotid dissection extending to the thoracic aorta, thus precluding the initiation of thrombolytic therapy with a potential deadly consequence. The turn-around time for these imaging studies should not delay therapeutic interventions. It is important that the emergency physician have baseline foundation on CT imaging interpretations and the ability to identify the presence or absence of hemorrhage, mass, or dissection. This knowledge will allow therapeutic intervention to proceed while awaiting the official radiologist interpretation.

The diffusion-weighted magnetic resonance imaging (MR-DWI) is the most sensitive and specific technique for identifying acute infarction within minutes of occurrence. The combination of DWI with MR-perfusion will enable the identification of viable from nonviable hypoperfused brain tissues. Despite the sensitivity and specificity of MRI, obtaining the study could be time consuming and can also create a logistical nightmare, especially when time is of essence. The role of MRI in acute stroke triage is still debatable, although a study by Schellinger et al²⁵ demonstrated that the diagnostic evaluation consisting of the DWI, MRP, and intracranial MRA could all be performed within 10 minutes.

Protocols for MRI utilization vary from different institutions. The typical MRI stroke protocol consist of T2/FLAIR, T2 weighted, diffusion

Figure 4: PCA Infarct



This image shows an unenhanced CT scan of a patient with a PCA infarct. Because of the hypo-attenuation in the posterior circulation, and the risk for hemorrhagic transformation, the patient was not a tPA candidate.

(DWI), and perfusion (PWI). The FLAIR image is very sensitive in identifying acute thrombosis and subarachnoid hemorrhage, while the T2 weighted image is very sensitive in detecting loss of arterial flow signal in the presence of hyperacute stroke within minutes. According to Wintermark et al,²⁶ these studies could be performed in less than 30 minutes.

The AHA recommendation for imaging for patients within 3 hours of symptoms is either NECT or MRI before intravenous tPA administration to exclude ICH and to determine the presence or absence of hypodensity (CT) or hyperintensity (MRI) of ischemia. Also, the presence of hypointensity on CT scan that involves more than a third of the MCA territory is a contraindication to thrombolytic therapy (class I, level of evidence A).

Summary

Neurologic emergency from acute stroke carry a significant morbidity and potential mortality. If approached in a systematic fashion, emergency physicians can improve the chances for a good neurologic outcome from this critical illness. Emergency physicians need to be

aware of the most current recommendations and guidelines that would lead to a favorable patient outcome. With the many advances in basic and clinical research for acute stroke, there will be more clarity to some of these current controversies regarding the best care for patients with stroke.

References

1. Miniño AM, Murphy SL, Xu J, et al. National Vital Statistics Reports; vol 59 no 10. Hyattsville, MD: National Center for Health Statistics; 2011.
2. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics — 2011 update: A report from the American Heart Association. *Circulation* 2011;123:e18-e209. Epub 2010 Dec 15.
3. Centers for Disease Control and Prevention. Prevalence and most common causes of disability among adults — United States, 2005. *MMWR* 2009;58:421-426.
4. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics — 2009 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation* 2009;119:480-486.
5. National Stroke Association. *Stroke/Brain Attack Reporter's Handbook*. Englewood, CO: National Stroke Association; 1995.
6. Moulin T, Tatu L, Vuillier F, et al. Role of a stroke data bank in evaluating cerebral infarction subtypes: Patterns and outcome of 1,776 consecutive patients from

the Besançon stroke registry. *Cerebrovasc Dis* 2000;10:261-271.

7. Garcia JH, et al. In: Barnett HJM, et al, eds. *Stroke Pathophysiology, Diagnosis, and Management*. New York: Churchill Livingstone; 1992:125.
8. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): An observational study. *Lancet* 2008;372:1303-1309.
9. del Zoppo GJ, Saver JL, Jauch EC, et al. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator. *Stroke* 2009;
10. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. *N Engl J Med* 2008;359:1317-1329.
11. Larrue V, von Kummer RR, Müller A, et al. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: A secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). *Stroke* 2001;32:438-441.
12. Jauch EC, Cucchiara B, Adeoye O, et al. Part 11: Adult stroke. 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. *Circulation* 2010;122(suppl 3):S818-S828.
13. Paciaroni M, Caso V, Agnelli G. The concept of ischemic penumbra in stroke and therapeutic opportunities. *Eur Neurol* 2009;61:321-330.
14. Owen B. Blood pressure control in acute cerebrovascular disease. *J Clin Hypertens* (Greenwich) 2011;13:205-211.
15. Garg R, Chaudhuri A, Munschauer F, et al. Hyperglycemia, insulin, and acute ischemic stroke. A mechanistic justification for a trial of insulin infusion therapy. *Stroke* 2006;37:267-273.
16. Ribo M, Molina CA, Delgado P, et al. Hyperglycemia during ischemia rapidly accelerate brain damage in stroke patients treated with tPA. *J Cereb Blood Flow Metab* 2007; Feb. 14;Epub ahead of print.
17. Alvarez-Sabin J, Molina CA, Ribo M, et al. Impact of admission hyperglycemia on stroke outcome after thrombolysis: Risk stratification in relation to time to reperfusion. *Stroke* 2004;35:2493-2498.
18. Fuentes B, Castillo J, San Jose B, et al. The prognostic value of capillary glucose levels in acute stroke: The Glycemia in Acute Stroke (GLIAS) study. *Stroke* 2009;40:562-568.
19. Fuentes B, Ortega-Casarrubios MA, SanJose B, et al. Persistent hyperglycemia > 155 mg/dL in acute ischemic stroke patients: How well are we correcting it? Implications for outcome. *Stroke* 2010;41:2362-2365.
20. Baker L, Juneja R, Bruno A. Management of hyperglycemia in acute stroke. *Curr Treat Options Neurol* 2011;13:616-628.
21. Latchaw RE, Albert MJ, Lev MH, et al. AHA scientific statement: Recommendations for imaging in acute stroke. *Stroke* 2009;40:3646-3678.
22. De La Paz RL, Wippold FJ, Cornelius RS, et al. American College of Radiology ACR Appropriateness Criteria: Cerebrovascular disease. Available at: <http://www.acr.org/ac>. Accessed January 20, 2012.
23. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). *JAMA* 1995;274:1017-1025.
24. Larrue V, von Kummer RR, Muller A, et al. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with tissue plasminogen activator: A secondary analysis of the European Cooperative Acute Stroke Study (ECASS II). *Stroke* 2001;32:438.
25. Schellinger PD, Jansen O, Fiebich JB, et al. Feasibility and practicality of MR imaging of stroke in the management of hyperacute cerebral ischemia. *AJNR Am J Neuroradiol* 2000;21:1184-1189.
26. Wintermark M, Albers GW, Alexandrov AV, et al. Acute stroke imaging research roadmap. *AJNR Am J Neuroradiol* 2008;29:e23-30.

Physician CME Questions

1. The most common artery involved in ischemic stroke is:
 - A. anterior cerebral artery
 - B. posterior cerebral artery
 - C. middle cerebral artery
 - D. lenticulostriate arteries
2. The recommended door to reperfusion in acute stroke is:
 - A. 30 minutes
 - B. 60 minutes
 - C. 90 minutes
 - D. 120 minutes
3. The recommendation for blood pressure control in acute stroke patients is to:
 - A. aggressively reduce blood pressure to 160/80
 - B. titrate blood pressure control to the systolic blood pressure < 185
 - C. titrate blood pressure to a MAP of 110
 - D. reduce the BP by 10% of initial vital sign
4. Recent evidence suggests that some patients can receive thrombolytic treatment up to:
 - A. 3 hours after the onset of symptoms
 - B. 1 hour after arrival to the ED
 - C. 4.5 hours after the onset of symptoms

Emergency Medicine Reports

CME Objectives

Upon completion of this educational activity, participants should be able to:

- recognize specific conditions in patients presenting to the emergency department;
- apply state-of-the-art diagnostic and therapeutic techniques to patients with the particular medical problems discussed in the publication;
- discuss the differential diagnosis of the particular medical problems discussed in the publication;
- explain both the likely and rare complications that may be associated with the particular medical problems discussed in the publication.

CME Instructions

HERE ARE THE STEPS YOU NEED TO TAKE TO EARN CREDIT FOR THIS ACTIVITY:

1. Read and study the activity, using the provided references for further research.
2. Log on to www.cmecity.com to take a post-test; tests can be taken after each issue or collectively at the end of the semester. *First-time users will have to register on the site using the 8-digit subscriber number printed on their mailing label, invoice, or renewal notice.*
3. Pass the online tests with a score of 100%; you will be allowed to answer the questions as many times as needed to achieve a score of 100%.
4. After successfully completing the last test of the semester, your browser will be automatically directed to the activity evaluation form, which you will submit online.
5. **Once the completed evaluation is received, a credit letter will be e-mailed to you instantly.**

- D. 3 hours after arrival to the ED
5. The major danger in the administration of thrombolytics for stroke is:
 - A. intracerebral bleed
 - B. dysrhythmias
 - C. hyperglycemia
 - D. myocardial infarction
 6. A patient awakes with a right-sided hemiparesis and aphasia. Which of the following options is available to the patient?
 - A. transfer for intracerebral clot removal
 - B. early placement in a nursing home for rehabilitation
 - C. intravenous thrombolytics
 - D. elevation of the head of the bed
 7. Although the ideal glucose level is not known, recommendations suggest the glucose level should be:
 - A. reduced by 50% over 6 hours
 - B. kept below 100 mg/dL
 - C. kept below 150 mg/dL
 - D. left alone to protect the penumbra
 8. Risk factors for stroke include all of the following *except*:
 - A. hypertension
 - B. African-American race
 - C. alcoholism
 - D. atrial fibrillation
 9. A stroke in the anterior cerebral artery circulation may present with which of the following?
 - A. visual loss
 - B. change in color vision
 - C. homonymous hemianopia
 - D. inability to speak or move
 10. A stroke in the posterior circulation may present with which of the following?
 - A. color vision loss
 - B. cortical blindness
 - C. right-left confusion
 - D. ataxia

To reproduce any part of this newsletter for promotional purposes, please contact:

Stephen Vance

Phone: (800) 688-2421, ext. 5511

Fax: (800) 284-3291

Email: stephen.vance@ahcmedia.com

To obtain information and pricing on group discounts, multiple copies, site-licenses, or electronic distribution please contact:

Tria Kreutzer

Phone: (800) 688-2421, ext. 5482

Fax: (800) 284-3291

Email: tria.kreutzer@ahcmedia.com

Address: AHC Media
3525 Piedmont Road, Bldg. 6,
Ste. 400, Atlanta, GA 30305 USA

To reproduce any part of AHC newsletters for educational purposes, please contact:

The Copyright Clearance Center for permission

Email: info@copyright.com

Website: www.copyright.com

Phone: (978) 750-8400

Fax: (978) 646-8600

Address: Copyright Clearance Center
222 Rosewood Drive, Danvers, MA 01923 USA

Editors

Sandra M. Schneider, MD

Professor
Department of Emergency Medicine
University of Rochester School of
Medicine
Rochester, New York

J. Stephan Stapczynski, MD

Chair
Emergency Medicine Department
Maricopa Medical Center
Phoenix, Arizona

Editorial Board

Paul S. Auerbach, MD, MS, FACEP

Professor of Surgery
Division of Emergency Medicine
Department of Surgery
Stanford University School of
Medicine
Stanford, California

Brooks F. Bock, MD, FACEP

Professor
Department of Emergency Medicine
Detroit Receiving Hospital
Wayne State University
Detroit, Michigan

William J. Brady, MD, FACEP, FAAEM

Professor and Vice Chair of
Emergency
Medicine, Department of Emergency
Medicine,
University of Virginia School of
Medicine
Charlottesville, Virginia

Kenneth H. Butler, DO FACEP, FAAEM

Associate Professor, Associate
Residency Director
University of Maryland Emergency
Medicine Residency Program
University of Maryland School
of Medicine
Baltimore, Maryland

Michael L. Coates, MD, MS

Professor and Chair
Department of Family and
Community Medicine
Wake Forest University School
of Medicine
Winston-Salem, North Carolina

Alasdair K.T. Conn, MD

Chief of Emergency Services
Massachusetts General Hospital
Boston, Massachusetts

Charles L. Emerman, MD

Chairman
Department of Emergency Medicine
MetroHealth Medical Center
Cleveland Clinic Foundation
Cleveland, Ohio

Kurt Kleinschmidt, MD, FACEP, FACMT

Professor of Surgery/Emergency
Medicine
Director, Section of Toxicology
The University of Texas
Southwestern Medical Center and
Parkland Hospital
Dallas, Texas

David A. Kramer, MD, FACEP, FAAEM

Program Director,
Emergency Medicine Residency
Vice Chair
Department of Emergency Medicine
York Hospital
York, Pennsylvania

Larry B. Mellick, MD, MS, FAAP, FACEP

Professor, Department of Emergency
Medicine and Pediatrics
Medical College of Georgia
Augusta, Georgia

Paul E. Pepe, MD, MPH, FACEP, FCCM, MACP

Professor of Medicine, Surgery,
Pediatrics, Public Health and Chair,
Emergency Medicine
The University of Texas

Southwestern Medical Center and
Parkland Hospital
Dallas, Texas

Charles V. Pollack, MA, MD, FACEP

Chairman, Department of Emergency
Medicine, Pennsylvania Hospital
Associate Professor of Emergency
Medicine
University of Pennsylvania School of
Medicine
Philadelphia, Pennsylvania

Robert Powers, MD, MPH

Professor of Medicine and
Emergency
Medicine
University of Virginia
School of Medicine
Charlottesville, Virginia

David J. Robinson, MD, MS, FACEP

Vice-Chairman and Research Director
Associate Professor of Emergency
Medicine
Department of Emergency Medicine
The University of Texas - Health
Science Center at Houston
Houston, Texas

Barry H. Rumack, MD

Director, Emeritus
Rocky Mountain Poison and Drug
Center
Clinical Professor of Pediatrics
University of Colorado Health
Sciences Center
Denver, Colorado

Richard Salluzzo, MD, FACEP

Chief Executive Officer
Wellmont Health System
Kingsport, Tennessee

John A. Schriver, MD

Chief, Department of Emergency
Services
Rochester General Hospital
Rochester, New York

David Sklar, MD, FACEP

Professor of Emergency Medicine

Associate Dean, Graduate Medical
Education
University of New Mexico School of
Medicine
Albuquerque, New Mexico

Charles E. Stewart, MD, FACEP

Professor of Emergency Medicine,
Director, Oklahoma Disaster Institute
University of Oklahoma, Tulsa

Gregory A. Volturo, MD, FACEP

Chairman, Department of Emergency
Medicine
Professor of Emergency Medicine
and Medicine
University of Massachusetts Medical
School
Worcester, Massachusetts

Albert C. Weihl, MD

Retired Faculty
Yale University School of Medicine
Section of Emergency Medicine
New Haven, Connecticut

Steven M. Winograd, MD, FACEP

St. Barnabus Hospital
Core Faculty
Emergency Medicine Residency
Program
Albert Einstein Medical School
Bronx, New York

Allan B. Wolfson, MD, FACEP, FACP

Program Director,
Affiliated Residency in Emergency
Medicine
Professor of Emergency Medicine
University of Pittsburgh
Pittsburgh, Pennsylvania

CME Question Reviewer

Roger Farel, MD

Retired
Newport Beach, CA

© 2012 AHC Media. All rights
reserved.

Emergency Medicine Reports™ (ISSN 0746-2506)
is published biweekly by AHC Media, a division of
Thompson Media Group LLC, 3525 Piedmont Road,
N.E., Six Piedmont Center, Suite 400, Atlanta, GA 30305.
Telephone: (800) 688-2421 or (404) 262-7436.

Senior Vice President/Group Publisher:

Donald R. Johnston

Executive Editor:

Shelly Morrow Mark

Managing Editor:

Leslie Hamlin

GST Registration No.:

R128870672

Periodicals Postage Paid at Atlanta, GA 30304 and at
additional mailing offices.

POSTMASTER: Send address
changes to Emergency Medicine
Reports, P.O. Box 105109, Atlanta,
GA 30348.

Copyright © 2012 by AHC Media, Atlanta, GA. All rights
reserved. Reproduction, distribution, or translation
without express written permission is strictly prohibited.

Back issues: \$31. Missing issues will be fulfilled by
customer service free of charge when contacted within
one month of the missing issue's date.

Multiple copy prices: One to nine additional copies, \$359
each; 10 to 20 additional copies, \$319 each.

Subscriber Information

Customer Service: 1-800-688-2421

Customer Service E-Mail:
customerservice@ahcmedia.com

Editorial E-Mail:
shelly.mark@ahcmedia.com

World Wide Web page:
http://www.ahcmedia.com

Subscription Prices

1 year *with* 60 ACEP/65 AMA/39 AAFP
Category 1/Prescribed credits: \$544

1 year *without* credit: \$399
Add \$17.95 for shipping & handling

Resident's rate \$199

Discounts are available for group
subscriptions, multiple copies, site-licenses
or electronic distribution. For pricing
information, call
Tria Kreutzer at 404-262-5482.

All prices U.S. only.
U.S. possessions and Canada, add \$30
plus applicable GST. Other international
orders, add \$30.

Accreditation

AHC Media is accredited by the
Accreditation Council for Continuing
Medical Education to provide continuing
medical education for physicians.

AHC Media designates this enduring
material for a maximum of *65 AMA PRA
Category 1 Credits™*. Each issue has been
designated for a maximum of *2.50 AMA
PRA Category 1 Credits™*. Physicians
should claim only credit commensurate
with the extent of their participation in the
activity.

Approved by the American College of
Emergency Physicians for 60 hours of
ACEP Category 1 credit.

This Enduring Material activity, *Emergency
Medicine Reports*, has been reviewed
and is acceptable for up to 39 Prescribed
credit(s) by the American Academy of
Family Physicians. AAFP accreditation
begins January 1, 2012. Term of approval
is for one year from this date with the
option of yearly renewal. Each issue is
approved for 1.50 Prescribed credits.
Physicians should claim only the credit
commensurate with the extent of their
participation in the activity.

Please forward your comments on the
quality of this activity to [cmecomment@
aafp.org](mailto:cmecomment@aafp.org).

This is an educational publication
designed to present scientific information
and opinion to health professionals,
to stimulate thought, and further
investigation. It does not provide
advice regarding medical diagnosis or
treatment for any individual case. It is not
intended for use by the layman. Opinions
expressed are not necessarily those of
this publication. Mention of products or
services does not constitute endorsement.
Clinical, legal, tax, and other comments
are offered for general guidance only;
professional counsel should be sought for
specific situations.

This CME activity is intended for
emergency and family physicians. It is in
effect for 24 months from the date of the
publication.

© 2012 AHC Media. All rights reserved.

AHC Media

Stroke Syndromes

Vessel	Territory	Clinical Presentation
Anterior cerebral	Frontal lobes Personality, voluntary movement	Uncommon stroke. Unilateral may be silent Contralateral leg weakness Bilateral: akinetic mutism (inability to move or speak) Confusion
Middle cerebral	Some frontal lobe Lateral surface of temporal and parietal lobes Basal ganglia Anterior/posterior internal capsules	Contralateral ataxia and hemiparesis Inability to write, calculate, right-left confusion Contralateral homonymous hemianopia, receptive aphasia, apraxia Contralateral hemiparesis, facial weakness, sensory loss, expressive aphasia
Posterior cerebral	Temporal lobe Occipital lobe	Lethargy/agitation, hemiplegia hemisensory loss, ophthalmoplegia Homonymous hemianopia Visual agnosia Inability to interpret vision, poor hand eye coordination, apraxia of gaze Inability to recognize faces Alexia (inability to read) Disorder of color vision Memory impairment Contralateral ataxia, oculomotor palsy Cortical blindness (Anton syndrome) Contralateral hemisensory loss or pain (thalamic syndrome) Contralateral hemiparesis with lateral gaze weakness (Weber syndrome) Locked in
Basilar	Cerebellum, pons, brainstem	Cortical blindness Contralateral hemiparesis, ipsilateral facial and lateral gaze weakness
Vertebral artery	Brainstem, cerebellum	Ipsilateral facial sensory loss and pain, ataxia, nystagmus, Horner's syndrome, contralateral hemisensory loss to pain and temperature (Wallenberg syndrome)
Lenticulostriate arteries	Deep branches off MCA	Lacunar infarctions

Adapted from www.strokecenter.org. Accessed April 2012.


Inclusion and Exclusion Criteria for Intravenous tPA Therapy in Patients with Acute Ischemic Stroke

tPA Indications
<ul style="list-style-type: none"> Ischemic stroke onset within 3 hours of drug administration. Measurable deficit on NIH Stroke Scale examination. Patient's computed tomography (CT) does not show hemorrhage or non stroke cause of deficit. Patient's age is > 18 years.
<p>Do NOT administer tPA if any of these statements are true:</p> <ul style="list-style-type: none"> Patient's symptoms are minor or rapidly improving. Patient had seizure at onset of stroke. Patient has had another stroke or serious head trauma within the past 3 months. Patient had major surgery within the last 14 days. Patient has known history of intracranial hemorrhage. Patient has sustained systolic blood pressure > 185 mmHg. Patient has sustained diastolic blood pressure > 110 mmHg. Aggressive treatment is necessary to lower the patient's blood pressure. Patient has symptoms suggestive of subarachnoid hemorrhage. Patient has had gastrointestinal or urinary tract hemorrhage within the last 21 days. Patient has had arterial puncture at noncompressible site within the last 7 days. Patient has received heparin with the last 48 hours and has elevated PTT. Patient's prothrombin time (PT) is > 15 seconds. Patient's platelet count is < 100,000 μL. Patient's serum glucose is < 50 mg/dL or > 400 mg/dL.
<p>tPA Relative Contraindications</p> <p>If either of the following statements is true, use tPA with caution:</p> <ul style="list-style-type: none"> Patient has a large stroke with NIH Stroke Scale score > 22. Patient's CT shows evidence of large middle cerebral artery (MCA) territory infarction (sulcal effacement or blurring of gray-white junction in greater than one-third of MCA territory).
<p>Adapted from the clinical policy of the American College of Emergency Physicians.</p>

Risk Factors for Stroke

Modifiable	Not Modifiable
<ul style="list-style-type: none"> High blood pressure Cigarette smoking Transient ischemic attacks Heart disease Diabetes mellitus Hypercoagulopathy Carotid stenosis Atrial fibrillation 	<ul style="list-style-type: none"> Age Gender Race (African American) Prior stroke Heredity (family history of stroke)

CT Angiogram of a Patient Showing Flow Pattern of the Right MCA Branch



Hyperdense MCA Sign



A noncontrast CT scan of the patient showing thrombus within the right MCA. This is referred to as the hyperdense MCA sign. This is one of the early signs of ischemia.

PCA Infarct



This image shows an unenhanced CT scan of a patient with a PCA infarct. Because of the hypo-attenuation in the posterior circulation, and the risk for hemorrhagic transformation, the patient was not a tPA candidate.

NIH Treatment Guideline/Sequence Considering the "Golden Hour"

Emergency department arrival to initial physician evaluation: **10 minutes**

Emergency department arrival to stroke team notification: **15 minutes**

Emergency department arrival to CT scan initiation: **25 minutes**

Door to CT scan interpretation: **< 45 minutes**

Cincinnati Prehospital Stroke Scale

	Normal	Abnormal
Facial Droop	Both sides of face move equally	One side of face does not move
Arm Drift	Both arms move equally	One arm drifts compared to the other
Speech	Patient uses correct words with no slurring	Slurred or inappropriate words or mute

Supplement to *Emergency Medicine Reports*, April 9, 2012: "The Evidence-based Approach to Neurologic Emergencies: Part I: Acute Stroke." *Author: Ademola Adewale, MD, FAAEM, Assistant Professor of Emergency Medicine, Florida State University College of Medicine, Director of Research and Medical Simulation, Florida Hospital Emergency Medicine Residency Program, Orlando, FL. Emergency Medicine Reports' "Rapid Access Guidelines."* Copyright © 2012 AHC Media, a division of Thompson Media Group LLC, Atlanta, GA. **Editors:** Sandra M. Schneider, MD, FACEP, and J. Stephan Stapczynski, MD. **Senior Vice President/Group Publisher:** Donald R. Johnston. **Executive Editor:** Shelly Morrow Mark. **Managing Editor:** Leslie Hamlin. For customer service, call: **1-800-688-2421**. This is an educational publication designed to present scientific information and opinion to health care professionals. It does not provide advice regarding medical diagnosis or treatment for any individual case. Not intended for use by the layman.